Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data

• DOI: 10.1186/s10020-019-0098-x
• Publication Date: 2019-06-20T10:02:46Z
• Authors: Ali Khosravi; B. Jayaram; Bahram Goliaei; Ali Masoudi-Nejad
• Keywords: DrugBank; Drug repositioning; Repurposing; Druggability; Phenome; Genome-wide Association Study; Omics

Drug repurposing is a swift, safe, and cheap drug discovery method. Melanoma disorders present low survival high mortality rates are challenging to diagnose treat. Moreover, there volume of worldwide investigations that attempting find melanoma-related genes influence, which can be identified as responsive targets for reliable treatment. In this study, we used wide range data analyses analyze over 1100 proteins influence with respect cutaneous malignant melanoma. Our analysis included various investigational results from genome- phenome-wide association studies (GWAS PheWAS, respectively), biomedical, transcriptomic, metabolomic datasets. We then researched the DrugBank potential melanoma selected list. excluded known obtain list druggable proteins. performed precise drugs’ pathogenesis checked expression profiles drugs having associations anti-melanoma drugs. found 35 interacted 20 unique targets. These appear have treatment potentials. confirmed our previous supporting references 30 these conclusion, investigation applied diseases efficient economical compounds. For further validation, may applicable in vivo tests clinical trials.